Posadas-Romero C, Posadas-Sánchez R, Juárez-Rojas JG, Medina-Urrutia A, Jorge-Galarza E, Cardoso-Saldaña G, Caracas-Portilla N, Mendoza-Pérez E

Idioma: Español
Referencias bibliográficas: 47
Paginas: 30-39
Archivo PDF: 148.50 Kb.

RESUMEN

Objetivo: Investigar la distribución de las subclases de las lipoproteínas de alta densidad (HDL) y su composición química, así como el tamaño y oxidabilidad de las lipoproteínas de baja densidad (LDL), en hombres con enfermedad arterial coronaria (EAC) tratados con estatinas, y colesterol de LDL en valores meta (‹ 100 mg/dL), pero con concentraciones anormales de colesterol HDL (‹ 40 mg/dL) y triglicéridos (TG ³ 150 mg/dL). El grupo control estuvo formado por hombres con EAC, tratados con estatinas, que tenían C-LDL en meta y valores normales de C-HDL y TG. Material y métodos: Las subclases de HDL y el tamaño de LDL se determinaron mediante electroforesis en gel de gradiente. La susceptibilidad de LDL a la oxidación se determinó midiendo la duración de la fase de latencia después de agregar el agente oxidante. Resultados: En comparación con el grupo control (n = 35), los pacientes con C-HDL bajo y TG altos (n = 34) se caracterizaron por tener proporciones menores de HDL grandes y mayores de HDL pequeñas. Además, estos pacientes tuvieron HDL de composición anormal y LDLs de tamaño menor y más susceptibles a la oxidación (p ‹ 0.05 para todas las diferencias). Conclusiones: Los pacientes coronarios con C-LDL ‹ 100 mg/dL en respuesta a estatinas, pero con C-HDL bajo y TG altos, tienen anormalidades en las características de HDL y LDL que se asocian con un riesgo más alto de eventos coronarios recurrentes.

REFERENCIAS (EN ESTE ARTÍCULO)

1. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.

2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. N Engl J Med 2004; 350: 1495-1504.

3. La Rosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al: Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.

4. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.

5. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-219.

6. Williams PT, Krauss RM, Nichols AV, Vranizan KM, Wood PD: Identifying the predominant peak diameter of high-density and low-density lipoproteins by electrophoresis. J Lipid Res 1990; 31: 1131-1139.

7. von Eckardstein A, Huang Y, Assmann G: Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 1994; 5: 404-416.

8. Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23: 1881-1888.

9. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-714.

10. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, et al: Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005; 25: 2185-2191.

11. Kontush A, de Faria EC, Chantepie S, Chapman MJ: A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 2005; 182: 277-285.

12. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, et al: Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89: 4963-4971.

13. Calabresi L, Gomaraschi M, Villa B, Omoboni L, Dmitrieff C, Franceschini G: Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-Cholesterol. Arterioscler Thromb Vasc Biol 2002; 22: 656-661.

14. Brites FD, Bonavita CD, De Geitere C, Cloes M, Delfly B, Yael MJ, et al: Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis 2000; 152: 181-192.

15. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ: Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002; 164: 361-369.

16. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-2756.

17. Barter P, Gotto A, La Rosa J, Grundy S, Kastelein J, Bittner V, et al: On-treatment levels of HDL-C and the ratio of LDL-C/HDL-C as predictors of cardiovascular events in the treating to new targets (TNT) study. ACC 55th Annual Scientific 2006 (Abstract): 914-203.

18. Barengo NC, Hu G, Lakka TA, Pekkarinen H, Nissinen A, Tuomilehto J: Low physical activity as a predictor for total and cardiovascular disease mortality in middle-aged men and women in Finland. Eur Heart J 2004; 25: 2204-2211.

19. Andersen LB, Schnohr P, Schroll M, Hein HO: All-cause mortality associated with physical activity during leisure time, work, sports, and cycling to work. Arch Intern Med 2000; 160: 1621-1628.

20. Sánchez-Castillo CP, Velázquez-Monroy O, Berber A, Lara-Esqueda A, Tapia-Conyer R, James WP: Anthropometric cutoff points for predicting chronic diseases in the Mexican National Health Survey 2000. Obes Res 2003; 11: 442-451.

21. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, et al: Direct measurement of High-Density lipoprotein cholesterol in serum with polyethylene gycol-modified enzymes and sufated a-cyclodextrin. Clin Chem 1995; 41: 717-723.

22. De Long D, De Long E, Wood P, Lippel K, Rifkind BM: A comparison of methods for the estimation of plasma low- and very low- density lipoprotein cholesterol. JAMA 1986; 256: 2372-2377.

23. Tailleux A, Torpier G, Caron B, Fruchart JC, Fievet C: Immunological properties of apo B- containing lipoprotein particles in human atherosclerotic arteries. J Lipid Res 1993; 34: 719-728.

24. Blanche P, Gong E, Forte T, Nichols AV: Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981; 665: 408-419.

25. Perusse M, Pascot A, Despres JP, Couillard C, Lamarche B: A new method for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole plasma. J Lipid Res 2001; 42: 1331-1334.

26. Laemmli U: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.

27. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23: 97-104.

28. Esterbauer H, Striegl G, Puhl H, Rotheneder M: Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989; 6: 67-75.

29. Godsland IF, Crook D, Walton C, Wynn V, Oliver MF: Influence of insulin resistance, secretion, and clearance on serum cholesterol, triglycerides, lipoprotein cholesterol, and blood pressure in healthy men. Arterioscler Thromb 1992; 12: 1030-1035.

30. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al: Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453-462.

31. Puchois P, Kandoussi A, Fievet P, Fourrier JL, Bertrand M, Koren E, et al: Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987; 68: 35-40.

32. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373-381.

33. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, et al: Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 2670-2676.

34. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, et al: High-Density Lipoprotein Subpopulation Profile and Coronary Heart Disease Prevalence in Male Participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004; 24: 2181-2187.

35. Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Chiesa G, Sirtori CR: Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hipercolesterolemia. J Lab Clin Med 1989; 114: 250-259.

36. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Nakamura H: Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis 1995; 114: 223-234.

37. Asztalos BF, MCTaggarr F, Horvath KV, Lemaulf F, Dallal GE, Schaefer EJ: Effect of maximal statin therapy on the high density lipoprotein (HDL) subpopulation profiles of hypercholesterolemic subjects. (Abstract). Atherosclerosis supplements 2006; 7: 580.

38. Assmann G, Nofer JR: Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003; 54: 321-341.

39. Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR: High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999; 274: 33143-33147.

40. Barter PJ, Baker PW, Rye KA: Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol 2002; 13: 285-288.

41. Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR, Barter PJ: Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 1450-1455.

42. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 1997; 95: 69-75.

43. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882-888.

44. Dejager S, Bruckert E, Chapman MJ: Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34: 295-308.

45. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-1792.

46. Salonen R, Nyssonen K, Porkkala-Sarataho E, Salonen JT: The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995; 76: 34C-39C.

47. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, et al: Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003; 23: 847-852.